Introduction: Esophageal cancer is a significant public health issue. According to the National Cancer Institute (INCA), it is the eighth most prevalent cancer worldwide. In Brazil, an estimated 10,990 new cases are expected to be diagnosed annually through 2025. Most cases are concentrated in the Southeast and South regions of the country; however, there is a scarcity of epidemiological studies in the Amazon region. In this context, this study aims to clarify the epidemiology of this disease in that Brazilian region. Objectives: To describe the cases of malignant neoplasms of the esophagus in the Brazilian Amazon region over the past decade. Methodology: This is a retrospective ecological time-series study. Data were collected through the Department of Informatics of the Brazilian Unified Health System (DATASUS), specifically from the ONCOLOGY Panel. The variables analyzed were: diagnosis (CID-10: C15 – malignant neoplasm of the esophagus), number of cases, year of notification (2014 to 2024), age group, gender, states comprising the Amazon region (Acre, Amapá, Amazonas, Maranhão, Mato Grosso, Pará, Rondônia, Roraima, Tocantins), lesion stage, and type of therapy. The results obtained were organized in a spreadsheet and analyzed using descriptive statistics. As these are secondary data, approval from the Research Ethics Committee was not required, according to CNS Resolution No. 510/2016. Results: During the analyzed period, 3,031 cases of malignant esophageal neoplasms were recorded. In 2014, there were 171 cases (5.6%), and in 2024 there were 320 cases (10.5%), with the highest number recorded in 2023, totaling 375 cases (12.3%) in the region. The age groups with the highest prevalence were 55–59 years, with 532 cases (17.5%), 60–64 years with 518 cases (17%), and 65–69 years with 501 cases (16.5%). There were 637 cases (21%) in females and 2,394 (79%) in males. Regarding the states within the Amazon region, the state of Mato Grosso accounted for a large portion of the cases, with 875 cases (28.8%), followed by Maranhão with 579 cases (19%) and Pará with 463 cases (15.2%). As for tumor staging (T), 59 lesions (2%) were classified as T0, 69 as T1 (2.2%), 604 as T2 (20%), and 1,724 (56.8%) as T3 and T4. Approximately 20% of the cases did not have staging information recorded. Regarding the proposed treatment, 44.6% of the cases received chemotherapy, 31% received radiotherapy, 5.2% received both treatments, and 4.5% underwent surgical management. Conclusion: The study showed a significant increase in cases of esophageal cancer in the Amazon region in the last decade. The highest incidence was observed in males and in individuals between the 5th and 7th decades of life. In addition, most cases were diagnosed in advanced stages (T3 and T4) and the most commonly used therapeutic modalities were chemotherapy and radiotherapy, indicating the predominance of treatments indicated for later stages of the disease. This reinforces the need for prevention, screening, early diagnosis and increased access to specialized oncology services. In this sense, the data presented can contribute to strengthening health strategies in the Brazilian Amazon region.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
